Corporate Crime in the Pharmaceutical Industry

Corporate Crime in the Pharmaceutical Industry examines how pharmaceutical companies engage in criminal practices and regulatory violations. Drawing from extensive research and interviews, criminologist John Braithwaite documents cases of fraud, bribery, and unsafe drug practices across the global pharmaceutical sector. The book presents detailed analysis of key issues including data manipulation in drug trials, marketing of dangerous medications, and corruption in drug approval processes. Braithwaite investigates incidents across multiple countries and companies, constructing a comprehensive picture of systemic problems within the industry. This work combines academic research with investigative reporting to explore how corporate structures and profit motives enable criminal behavior. The text includes extensive documentation and first-hand accounts from industry insiders. The book remains a foundational text in corporate crime studies, highlighting enduring questions about corporate accountability and public health. Its examination of how organizational cultures can normalize unethical practices offers insights relevant to modern corporate oversight and regulation.

Readers describe this book as a detailed investigation that exposes fraudulent practices in pharmaceutical companies, based on hundreds of interviews with industry insiders. Social scientists and policy researchers reference it frequently. Positive points: - Thorough documentation of corporate misconduct cases - Clear explanations of complex regulatory issues - Useful historical context that remains relevant today - Strong research methodology Negative points: - Dense academic writing style - Data and examples from 1984 are dated - Limited discussion of potential solutions - Some sections repeat information Ratings: Goodreads: 4.2/5 (32 ratings) Google Books: 4/5 (11 ratings) "Still the definitive text on pharmaceutical industry corruption" - Research Gate review "Important but dry reading" - Goodreads reviewer "The practices described continue today" - Academic citation on Google Scholar The book is frequently cited in academic papers but has limited reviews on consumer platforms.

Bad Pharma by Ben Goldacre Documents how pharmaceutical companies manipulate clinical trials, suppress data, and mislead doctors and regulators.

The Truth About the Drug Companies by Marcia Angell Examines pharmaceutical industry practices including pricing, marketing, research funding, and regulatory capture based on the author's experience as editor of The New England Journal of Medicine.

White-Collar Crime and Criminal Careers by David Weisburd and Elin Waring Analyzes patterns of corporate crime through case studies and statistical data focusing on repeat offenders and systemic issues.

Poison Pills: The Untold Story of the Vioxx Drug Scandal by Tom Nesi Chronicles the development, marketing, and eventual recall of Vioxx while revealing internal decision-making at Merck and regulatory failures.

The Rise of Big Pharma by Mickey C. Smith and Richard A. Young Traces the transformation of the pharmaceutical industry from small chemical companies to multinational corporations through key historical developments and policy changes.

🔍 John Braithwaite pioneered the concept of "regulatory capitalism" and has authored over 20 books on corporate crime and regulation during his distinguished academic career 💊 The book was researched during a period when several major pharmaceutical scandals were unfolding, including the Oraflex and Opren controversies of the early 1980s 🏢 Many of the corporate practices exposed in the book led to significant regulatory reforms, including the Prescription Drug Marketing Act of 1987 🌍 The research spanned multiple continents, with interviews conducted across the US, UK, Europe, and Australia to provide a global perspective on pharmaceutical industry practices 📈 The publication helped establish pharmaceutical crime as a distinct field of study within corporate criminology and influenced subsequent research in business ethics